Sobre mi

Josep M. Llovet, MD, PhD és Catedràtic de Medicina - Oncologia Hepàtica a la Universitat de Barcelona, Cap de Grup i Catedràtic de Recerca-ICREA a la unitat de fetge, IDIBAPS-Hospital Clínic i Director del Programa de Càncer Hepàtic i Catedràtic de Medicina a Icahn School of Medicine a Mount Sinai, NY. Ha dedicat la seva carrera a la patogènesis i tractament del càncer de fetge, publicant ~ 350 articles (~ 136.049 cites, índex h: 134) i liderant ~100 projectes. Ha estat nominat com a investigador op 1% més citat mundialment (2014 a 2022) i nominat Editor en Cap de JHEP Reports (2024-29).

Publicacions destacades

  • Molecular markers of response to anti-PD1 therapy in advanced hepatocellular carcinoma

    Autors: Haber PK; Castet F; Torres-Martin M; Andreu-Oller C; Puigvehí M; Miho M; Radu P; Dufour JF; Verslype C; Czauderna C; Marquardt JU; Galle PR; Vogel A; Bathon M; Meyer T; Labgaa I; Digklia A; Roberts LR; Mohamed Ali MA; Mínguez B; Citterio D; Mazzaferro V; Finkelmeier F; Trojan J; Özdirik B; Müller T; Schmelzle M; Bejjani A; Sung MW; Schwartz ME; Finn RS; Thung S; Villanueva A; Sia D; Llovet JM.
    Referència: Gastroenterology 2023.
  • Inflamed and non-inflamed classes of HCC: a revised immunogenomic classification

    Autors: Montironi C, Castet F, Haber PK, Pinyol R, Torres-Martin M, Torrens L, Mesropian A, Wang H, Puigvehi M, Maeda M, Leow WQ, Harrod E, Taik P, Chinburen J, Taivanbaatar E, Chinbold E, Solé Arqués M, Donovan M, Thung S, Neely J, Mazzaferro V, Anderson J, Roayaie S, Schwartz M, Villanueva A, Friedman SL, Uzilov A, Sia D, Llovet JM .
    Referència: Gut 2023.
  • International Liver cancer Association (ILCA) White Paper on Hepatocellular carcinoma Risk Stratification and Surveillance

    Autors: Singal AG; Sanduzzi-Zamparelli M; Nahon P; Ronot M; Hoshida Y; Rich N; Reig M; Vilgrain V; Marrero J; Llovet JM; Parikh ND; Villanueva A.
    Referència: Journal Of Hepatology 2023.
  • Immunotherapies for hepatocellular carcinoma

    Autors: Llovet JM; Castet F; Heikenwalder M; Maini MK; Mazzaferro V; Pinato DJ; Pikarsky E; Zhu AX; Finn RS.
    Referència: Nature Reviews Clinical Oncology 2021.
  • Molecular characterization of hepatocellular carcinoma in patients with non-alcoholic steatohepatitis

    Autors: Pinyol R, Torrecilla S, Wang H, Montironi C, Piqué-Gili M, Torres-Martin M, Wei-Qiang L, Willoughby CE, Ramadori P, Andreu-Oller C, Taik P, Lee YA, Moeini A, Peix J, Faure-Dupuy S, Riedl T, Schuehle S, Oliveira CP, Alves VA, Boffetta P, Lachenmayer A, Roessler S, Minguez B, Schirmacher P, Dufour JF, Thung SN, Reeves HL, Carrilho FJ, Chang C, Uzilov AV, Heikenwalder M, Sanyal A, Friedman SL, Sia D, Llovet JM .
    Referència: Journal Of Hepatology 2021.
  • NASH limits anti-tumour surveillance in immunotherapy-treated HCC

    Autors: Pfister, Dominik; Nunez, Nicolas Gonzalo; Pinyol, Roser; Govaere, Olivier; Pinter, Matthias; Szydlowska, Marta; Gupta, Revant; Qiu, Mengjie; Deczkowska, Aleksandra; Weiner, Assaf; Mueller, Florian; Sinha, Ankit; Friebel, Ekaterina; Engleitner, Thomas; Lenggenhager, Daniela; Moncsek, Anja; Heide, Danijela; Stirm, Kristin; Kosla, Jan; Kotsiliti, Eleni; Leone, Valentina; Dudek, Michael; Yousuf, Suhail; Inverso, Donato; Singh, Indrabahadur; Teijeiro, Ana; Castet, Florian; Montironi, Carla; Haber, Philipp K.; Tiniakos, Dina; Bedossa, Pierre; Cockell, Simon; Younes, Ramy; Vacca, Michele; Marra, Fabio; Schattenberg, Jorn M.; Allison, Michael; Bugianesi, Elisabetta; Ratziu, Vlad; Pressiani, Tiziana; D'Alessio, Antonio; Personeni, Nicola; Rimassa, Lorenza; Daly, Ann K.; Scheiner, Bernhard; Pomej, Katharina; Kirstein, Martha M.; Vogel, Arndt; Peck-Radosavljevic, Markus; Hucke, Florian; Finkelmeier, Fabian; Waidmann, Oliver; Trojan, Jorg; Schulze, Kornelius; Wege, Henning; Koch, Sandra; Weinmann, Arndt; Bueter, Marco; Rossler, Fabian; Siebenhuner, Alexander; De Dosso, Sara; Mallm, Jan-Philipp; Umansky, Viktor; Jugold, Manfred; Luedde, Tom; Schietinger, Andrea; Schirmacher, Peter; Emu, Brinda; Augustin, Hellmut G.; Billeter, Adrian; Mueller-Stich, Beat; Kikuchi, Hiroto; Duda, Dan G.; Kutting, Fabian; Waldschmidt, Dirk-Thomas; Ebert, Matthias Philip; Rahbari, Nuh; Mei, Henrik E.; Schulz, Axel Ronald; Ringelhan, Marc; Malek, Nisar; Spahn, Stephan; Bitzer, Michael; Ruiz de Galarreta, Marina; Lujambio, Amaia; Dufour, Jean-Francois; Marron, Thomas U.; Kaseb, Ahmed; Kudo, Masatoshi; Huang, Yi-Hsiang; Djouder, Nabil; Wolter, Katharina; Zender, Lars; Marche, Parice N.; Decaens, Thomas; Pinato, David J.; Rad, Roland; Mertens, Joachim C.; Weber, Achim; Unger, Kristian; Meissner, Felix; Roth, Susanne; Jilkova, Zuzana Macek; Claassen, Manfred; Anstee, Quentin M.; Amit, Ido; Knolle, Percy; Becher, Burkhard; Llovet, Josep M.; Heikenwalder, Mathias;.
    Referència: Nature 2021.
  • Hepatocellular carcinoma

    Autors: Llovet JM; Kelley RK; Villanueva A; Singal AG; Pikarsky E; Roayaie S; Lencioni R; Koike K; Zucman-Rossi J; Finn RS.
    Referència: Nature Reviews Disease Primers 2021.
  • Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets

    Autors: Schulze K., Imbeaud S., Letouzé E., Alexandrov L.B., Calderaro J., Rebouissou S., Couchy G., Meiller C., Shinde J., Soysouvanh F., Calatayud A.L., Pinyol R., Pelletier L., Balabaud C., Laurent A., Blanc J.F., Mazzaferro V., Calvo F., Villanueva A., Nault J.C., Bioulac-Sage P., Stratton M.R., Llovet J.M., Zucman-Rossi J..
    Referència: Nature Genetics 2015.
  • Sorafenib in Advanced Hepatocellular Carcinoma

    Autors: Llovet, JM; Ricci, S; Mazzaferro, V; Hilgard, P; Gane, E; Blanc, JF; de Oliveira, AC; Santoro, A; Raoul, JL; Forner, A; Schwartz, M; Porta, C; Zeuzem, S; Bolondi, L; Greten, TF; Galle, PR; Seitz, JF; Borbath, I; Haussinger, D; Giannaris, T; Shan, M; Moscovici, M; Voliotis, D; Bruix, J.
    Referència: New England Journal Of Medicine 2008.
  • Gene Expression in Fixed Tissues and Outcome in Hepatocellular Carcinoma

    Autors: Hoshida, Yujin; Villanueva, Augusto; Kobayashi, Masahiro; Peix, Judit; Chiang, Derek Y; Camargo, Amy; Gupta, Supriya; Moore, Jamie; Wrobel, Matthew J; Lerner, Jim; Reich, Michael; Chan, Jennifer A; Glickman, Jonathan N; Ikeda, Kenji; Hashimoto, Masaji; Watanabe, Goro; Daidone, Maria G; Roayaie, Sasan; Schwartz, Myron; Thung, Swan; Salvesen, Helga B; Gabriel, Stacey; Mazzaferro, Vincenzo; Bruix, Jordi; Friedman, Scott L; Kumada, Hiromitsu; Llovet, Josep M; Golub, Todd R.
    Referència: New England Journal Of Medicine 2008.

Projectes destacats

  • Laboratori de Recerca Translacional en Oncologia Hepàtica

    Investigador/a principal: Josep M. Llovet Bayer
    Finançador: Agencia de Gestio d'Ajuts Universitaris i de Recerca (AGAUR)
    Codi: AGAUR_SGR21
    Durada: 01/01/2022 - 31/12/2024
  • Identification of biomarkers predicting response and resistance to immunotherapy in advanced hepatocellular carcinoma

    Investigador/a principal: Josep M. Llovet Bayer
    Finançador: Asociación Española Contra el Cáncer
    Durada: 01/12/2021 - 30/11/2025
  • Molecular characterization of obesity/diabetes/NASH-related hepatocellular carcinoma

    Investigador/a principal: Josep M. Llovet Bayer
    Finançador: Agencia Estatal de Investigación
    Codi: PID2019-105378RB-100
    Durada: 01/06/2020 - 31/05/2023
  • HUNTER-Hepatocellular Carcinoma Expediter Network

    Investigador/a principal: Josep M. Llovet Bayer
    Finançador: Asociación Española Contra el Cáncer (AECC)
    Codi: AECC_AccAward17
    Durada: 01/12/2018 - 30/11/2025
  • Mecanismos de resistencia adquirida a sorafenib en el carcinoma hepatocelular

    Investigador/a principal: Josep M. Llovet Bayer
    Finançador: Ministerio de Economía y Competitividad
    Codi: SAF2016-76390-R
    Durada: 31/12/2016 - 10/01/2020